MEDICORTEX-FINLAND
29.8.2018 11:19:21 CEST | Business Wire | Press release
Medicortex Finland today announced that the Ethics Committee approved an additional site in the second clinical trial of ProbTBI™, a diagnostic kit for mild Traumatic Brain Injury (TBI) detection. Accelerated recruitment of patients will be performed in the central hospitals of Turku, Pori and Vaasa in Finland during the next few months.
The clinical trial is being conducted in Finland at three central hospital sites with first level emergency departments and high expertise in the TBI management. Patients with suspected mild TBI or concussion will be studied with respect to their specific biomarker signature in their bodily fluids and they will be compared to control patients with orthopedic injury and to healthy controls. Among the first target of 60 subjects, all healthy controls and more than half of the injured patients have been recruited until now. In the second stage the number of patients is extendable to 160. The study is posted in a public database where the status and progression are kept updated (www.ClinicalTrials.gov, NCT03306563 ).
"ProbTBI™ will be a highly innovative novel diagnostic kit for rapid detection of TBI and concussion. It is now further developed and evidenced in the ongoing clinical trial" said Dr. Adrian Harel, CEO of Medicortex. “Involvement of the third hospital will speed up the recruitment of patients and it will guarantee us adequate population for the next extended stage as we are now covering the entire Western Finland” Dr. Harel adds.
Dr. Mårten Kvist, Medical Director of Medicortex says: "A diagnostic tool for rapid detection of TBI is truly awaited and it will satisfy an urgent need to considerably improve the detection of brain injury in patients who are suffering a head injury without self-evident symptoms of brain damage.” and he adds that “By including sufficient number of patients in the clinical study Medicortex will justify the scientific and statistic strength of its biomarker detection assay.”
Medicortex Finland Oy is engaged in the development of first-of-its-kind diagnostic kit for rapid detection of concussion and mild TBI. The Company has the technology to capture biomarkers from noninvasive body fluid samples and to develop them into an affordable diagnostic tool. The patent portfolio held by Medicortex grants safety to develop the products. More information about TBI and its detection is available on Company's website at www.medicortex.fi
About Medicortex
Medicortex Finland Oy is a biotechnology company dedicated to improving the diagnostics and treatment of Traumatic Brain Injury (TBI). Its current focus is on developing biomarker diagnostics to detect the presence and severity of a head injury. Once the company completes the kit development, its next goal will be to develop an innovative drug to halt the progression of brain injury.
Key words: brain injury, head injury, concussion, diagnostics, TBI, early detection, trauma, clinical trial
View source version on businesswire.com: https://www.businesswire.com/news/home/20180829005262/en/
Contact:
Medicortex Finland Oy Dr. Adrian Harel - CEO Tel. +358 (0) 400 488 817 adrian.harel@medicortex.fi http://www.medicortex.fi
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kinaxis Announces Departure of Chief Financial Officer4.3.2026 23:00:00 CET | Press release
Leadership change comes as strong financial performance and AI-driven market momentum underpins long-term strategic growth Kinaxis® Inc. (TSX:KXS), a global leader in supply chain orchestration, today announced that Blaine Fitzgerald, Chief Financial Officer (CFO), has advisedof his intention to step down from his role to pursue a new career opportunity with a private company outside the supply chain software space. A search will begin for a new CFO immediately. Fitzgerald remains with the company as CFO through May 8, following the company’s first quarter 2026 earnings call, to support a smooth transition. “We are grateful for Blaine’s leadership and contributions over the past six years. He has played a key role in strengthening our financial foundation, building out the financial leadership team, and advancing our AI strategy. Thanks to the depth and capability of our Senior Leadership Team, we remain well-positioned for continued success as we begin the search for our next finance
IFF Declares Dividend for First Quarter 20264.3.2026 22:15:00 CET | Press release
IFF (NYSE: IFF) announced that its Board of Directors has declared a regular quarterly cash dividend of $0.40 per share of its common stock, payable on April 10, 2026 to shareholders of record as of March 20, 2026. Welcome to IFF At IFF (NYSE: IFF), we make joy through science, creativity and heart. As the global leader in flavors, fragrances, food ingredients, health and biosciences, we deliver groundbreaking, sustainable innovations that elevate everyday products—advancing wellness, delighting the senses and enhancing the human experience.Learn more at iff.com, LinkedIn, Instagram and Facebook. © 2026 by International Flavors & Fragrances Inc. IFF is a Registered Trademark. All Rights Reserved. View source version on businesswire.com: https://www.businesswire.com/news/home/20260304579613/en/
Armis Named a Leader for Second Consecutive Year in 2026 Gartner® Magic Quadrant™ for CPS Protection Platforms4.3.2026 16:12:00 CET | Press release
Armis CentrixTM leveraged by global organizations to manage cyber risk across their entire attack surface Armis, the cyber exposure management & security company, today announced that it has been named a Leader in the 2026 Gartner Magic Quadrant for CPS Protection Platforms for the second consecutive year. “In an era of agentic AI, the security of our cyber-physical systems has become a strategic imperative for enterprises and governments globally; it is a pivotal pillar of global stability,” said Yevgeny Dibrov, CEO and Co-Founder of Armis. “We believe this back-to-back recognition from Gartner reflects our continued commitment to helping organizations secure the complex, critical world of CPS and reinforces the strength of our unified, proactive platform approach. Our innovation pipeline, which is aligned with our customers' needs, will continue to prioritize protecting critical environments to keep society safe and secure.” Armis was named a Leader in this report among the 13 vendor
Svante Acquires Carbon Dioxide Removal Project Developer, Carbon Alpha Corp.4.3.2026 16:00:00 CET | Press release
Svante acquires Carbon Alpha to accelerate commercial-scale carbon removal & expand its CCS/BECCS project development business in Western Canada. Acquisition adds the North Star BECCS Project, developed in partnership with the Meadow Lake Tribal Council, advancing the market for durable and verifiable CDR credits. The transaction strengthens Svante’s fully integrated carbon management platform, adding CO₂ storage expertise, a regional pipeline & a major geological storage hub. Svante Technologies Inc. (Svante), a leader in carbon management, and Calgary-based Carbon Alpha Corporation (Carbon Alpha) today announced that Svante has acquired Carbon Alpha and its related subsidiaries, including Carbon Alpha Development Corp. and its ownership interests in North Star Carbon Solutions Corp. and North Star Carbon Solutions Limited Partnership, a project developer for carbon capture and storage (CCS) in Western Canada. With this transaction, Carbon Alpha’s flagship North Star Bioenergy Carbon
Binarly Announces Leadership Transition as Enterprise Demand Accelerates for Supply-Chain Security4.3.2026 16:00:00 CET | Press release
Binarly, the industry leader in software and firmware supply‑chain security, today announced a leadership transition as the company enters its next phase of growth. Founder and current CEO Alex Matrosov has joined the company’s Board, and Gwenyth Castro has joined as Chief Executive Officer to scale global go-to-market and enterprise growth. Binarly developed its Transparency Platform on a unique, patented technology core designed to help the world’s largest enterprises identify and reduce third-party software risk across complex environments. The platform is trusted by organizations including Meta and Dell, among others. “We built Binarly to solve a problem the industry kept ignoring: you can’t secure what you can’t see,” said Alex Matrosov, Founder of Binarly. “Over the last five years, this team turned deep program analysis and vulnerability research into a platform trusted by some of the world’s most demanding enterprises. Now, as AI accelerates how software is built and shipped, t
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom